Hernández-Yagüe Xavier Hernández-Yagüe

Mr. Hernández-Yagüe Xavier Hernández-Yagüe


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in European Journal of Cancer
Verified
Journal Article
Closed access
JRJ. Rubió
J. Rubió
Rafael Marcos-GrageraRafael Marcos-Gragera
Rafael Marcos-Gragera
RORosa Ortiz
Rosa Ortiz
JMJ. Miró
J. Miró
LVL. Vilardell
L. Vilardell
RCRamon Colomer
Ramon Colomer

22 November 2010 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
COCristina Oliveras‐Ferraros
Cristina Oliveras‐Ferraros
AVAlejandro Vazquez‐Martin
Alejandro Vazquez‐Martin
SCSílvia Cufí
Sílvia Cufí
BQBernardo Queralt
Bernardo Queralt
LBLuciana Báez
Luciana Báez
Javier A. MenendezJavier A. Menendez
Javier A. Menendez

1 December 2005 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HHHernández-Yagüe Xavier Hernández-Yagüe
Hernández-Yagüe Xavier Hernández-Yagüe
ESEster Soy
Ester Soy
BMBernardo Queralt Merino
Bernardo Queralt Merino
JPJosep Puig
Josep Puig
MFMiguel Beltrán Fabregat
Miguel Beltrán Fabregat
RCRamon Colomer
Ramon Colomer

1 March 2009 in European Journal Of Dermatology
Verified
Journal Article
Closed access
PDF file
JCJordi Rubió Casadevall
Jordi Rubió Casadevall
BGBegoña Graña-Suárez
Begoña Graña-Suárez
HHHernández-Yagüe Xavier Hernández-Yagüe
Hernández-Yagüe Xavier Hernández-Yagüe
JRJordi Vayreda Ribera
Jordi Vayreda Ribera
OGOscar Huc Grasa
Oscar Huc Grasa
JVJoan Brunet Vidal
Joan Brunet Vidal
Xeroderma pigmentosum is a genodermatosis characterized by defects in the DNA nucleotide excision repair pathway, which increases the risk of suffering skin cancers. There is lack of information about the efficacy and toxicity of chemotherapy and radiotherapy in the treatment of these patients. We present the case of a xeroderma pigmentosum patient with a neck node recurrence of a squamous cell skin carcinoma that achieved a good response and survival with cetuximab.

27 June 2022 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
JAJorge Aparicio
Jorge Aparicio
AMAnna C. Virgili Manrique
Anna C. Virgili Manrique
JCJaume Capdevila
Jaume Capdevila
FBFélix Muñoz Boza
Félix Muñoz Boza
PGPatricia Galván
Patricia Galván
Joan MaurelJoan Maurel
Joan Maurel
Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment forRASwild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with noRASmutations in liquid biopsy (LB).Methods: In this randomized phase II trial, patients were assigned (3:2 ratio) to second-line P-FOLFIRI (arm A) or FOLFIRI alone (arm B). LB for circulating tumor DNA analysis was collected at study entry and at disease progression. Primary endpoint was 6-month progression-free survival. Two-stage Simon design required 85 patients to be included (EudraCT 2017-004519-38).Results: Between February 2019 and November 2020, 49 patients were screened (16 RAS mutations in LB detected) and 31 included (18 assigned to arm A and 13 to arm B). The study was prematurely closed due to inadequate recruitment. Serious adverse events were more frequent in arm A (44% vs. 23%). Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B) (hazard ratio, 0.58). At disease progression,RASorBRAFmutations in LB were found in 4/11 patients (36%) in arm A and 2/10 (20%) in arm B.Conclusions: The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WTRASstatus selected by LB. This strategy deserves further investigation.

9 August 2011 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
Javier A. MenendezJavier A. Menendez
Javier A. Menendez
COCristina Oliveras-Ferraros
Cristina Oliveras-Ferraros
AVAlejandro Vazquez-Martin
Alejandro Vazquez-Martin
BQBernardo Queralt
Bernardo Queralt
MAManuel Adrados
Manuel Adrados
JBJoan Brunet
Joan Brunet
KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A significant number of mCRC patients with KRAS wild-type (WT) tumors, however, do not benefit from cetuximab. We are also lacking efficacy predictors in head and neck squamous cell carcinomas with an intact KRAS signaling and in non-small cell lung cancer in which KRAS mutations do not predict cetuximab efficacy. We recently established pre-clinical models of EGFR gene-amplified KRAS WT A431 squamous carcinoma cells chronically adapted to grow in the presence of cetuximab. We employed the ingenuity pathway analysis software to functionally interpret data from Agilent's whole human genome arrays in the context of biological processes, networks, and pathways. Cetuximab-induced activation of the interferon (IFN)/STAT1 appeared to switch from 'growth inhibitory' in acutely-treated cells to 'pro-survival' in chronically-adapted cells. Cetuximab treatment appeared to negatively select initially dominant IFN-sensitive clones and promoted selection of IFN- and cetuximab-refractory tumor clones constitutively bearing an up-regulated IFN/STAT1 signaling. High-levels of mRNAs coding for the EGFR ligands amphiregulin (AREG), epiregulin (EREG), and neuregulin-1/heregulin (NRG1) predicted for acute cetuximab's functioning. Chronic cetuximab, however, appeared to negatively select initially dominant AREG/EREG/NRG1-positive clones to promote selection of cetuximab-refractory clones exhibiting a knocked-down neuregulin signaling. Our current evolutionary mapping of the transcriptomic changes that occur during cetuximab-induced chronic blockade of EGFR/KRAS WT signaling strongly suggests that mRNAs coding for IFN/STAT1- and EGFR ligands-related genes can be evaluated as novel predictors of efficacy in KRAS WT squamous cancer patients being treated with cetuximab.